News and blogs
24 results found.
Blood cancer survivor is ‘luckiest man alive’ as treatment helps gain approval for use on NHS
England’s drug regulators have recommended two new treatments for blood cancer for use on the NHS.
Our highlights from the 2024 ASH conference
Read more on highlights from the 2024 annual American Society of Haematology (ASH) conference
New blood cancer drugs in Scotland approved
Regulators in Scotland, has approved two new blood cancer treatments for use on the NHS in Scotland. A CAR-T therapy for diffuse large B-cell lymphoma is one of the treatments.
World Cancer Research Day: our new research projects
We are funding eight new research projects we are funding taking our total number of research projects to 87 across the UK.
CAR-T therapy Kymriah available for a form of childhood and young-adult leukaemia on the NHS
'Life-changing' blood cancer drug, Kymriah is now available routinely on the NHS for childhood and young-adult B-cell acute lymphoblastic leukaemia on the NHS
How a Yorkshire house led to five pioneering research projects
Last year you raised an incredible £1.95m for Blood Cancer UK in the Omaze Millon Pound House Draw. Find out more about the incredible research projects this is helping to support.
Simon Thomas launches new blood cancer projects
Blood Cancer UK reveals that the money from their latest partnership with Omaze UK is their largest single donation to date. The money has now been invested into research via the Omaze x Blood Cancer UK Research Fund.
Scotland drug regulators rule blood cancer isn't cost effective
Yescarta, the blood cancer drug is not to be made available on the NHS in Scotland even though it is in England. Blood Cancer UK says it highlights the inequality in access to blood cancer drugs across the UK.
From despair to hope: The Matthew Wilson Multiple Myeloma Fund
Matthew Wilson establishes the Matthew Wilson Multiple Myeloma Fund (MWMMF) at Blood Cancer UK.
Blood Cancer UK fund new research
Blood Cancer UK are funding 16 new research projects worth £14 million
CAR-T cell therapy made available on NHS
Yescarta has now been made available for people with certain types of lymphoma on the NHS in England
EHA annual conference 2020: the promising future of blood cancer research
Blood Cancer UK rounds up the exciting breakthroughs in blood cancer research discussed at this year’s European Haematology Association conference.
Researchers say blood cancer beaten in a few decades
Blood cancer researchers are excited about the future and say the scientific progress made mean blood cancer can be beaten in the next few decades.
The American Society of Haematology (ASH) Annual Meeting saw 30,000 experts to discuss new research examining blood cancers and other blood disorders.
The American Society of Haematology (ASH) Annual Meeting saw 30,000 experts to discuss new research examining blood cancers and other blood disorders.
Meet the Scientists 2019 - highlights
The event showcases recent breakthroughs in blood cancer research. It's an opportunity to hear about the latest updates in treatments and technologies.
Blood cancer documentary gave me hope.
War in the Blood, a new BBC documentary follows two people who received CAR-T therapy, a groundbreaking new treatment for blood cancer, as part of a clinical trial. Kate, our Senior Support Services Manager, reviews the documentary.
CAR-T access in Scotland for childhood leukaemia
Children and young people in Scotland with ALL who relapse after standard treatments will be able to access the CAR-T cell therapy Kymriah.
Two breakthroughs in CAR-T therapy
First child with acute lymphoblastic leukaemia (ALL) receives CAR-T therapy on the NHS and the treatment is made available to adult lymphoma patients.
CAR-T therapies hold promise for cancers
Immunotherapy treatments called CAR-T therapies involve reprogramming a type of ‘supercharged’ immune cell could be mass-produced to help fight cancer.
CAR-T treatment turned down on NHS
The NHS medicines watchdog has recommended that a treatment called Kymriah should not be available to people with diffuse large B-cell lymphoma (DLBCL).